Vertex to end sales of hepatitis C drug Incivek
(Reuters) - Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc. (Source: Reuters: Health)
Source: Reuters: Health - August 13, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
telaprevir (Incivek)
Title: telaprevir (Incivek)Category: MedicationsCreated: 7/21/2014 4:15:00 PMLast Editorial Review: 7/21/2014 4:15:06 PM (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - July 21, 2014 Category: Gastroenterology Source Type: news
telaprevir (Incivek)
Title: telaprevir (Incivek)Category: MedicationsCreated: 7/21/2014 4:15:00 PMLast Editorial Review: 7/21/2014 4:15:06 PM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 21, 2014 Category: Drugs & Pharmacology Source Type: news
New hepatitis C drug treatment 'shows promise'
Conclusion
Although designed as an RCT, the study had an analysis of drug effectiveness that becomes more like a single cohort of people receiving an active treatment, with no comparison arm.
People were assigned to the five-drug combination or matching placebos for 12 weeks. During this time, the side effects in both treatment groups were monitored and these could be compared, with itching and anaemia occurring more commonly in the active treatment group.
However, the double-blind drug treatment period was completed at 12 weeks and response outcomes were then assessed 12 weeks later. Twelve weeks later, the active treatm...
Source: NHS News Feed - April 14, 2014 Category: Consumer Health News Tags: Medication Medical practice Source Type: news
New hepatitis C drug treatment 'shows promise'
Conclusion
Although designed as an RCT, the study had an analysis of drug effectiveness that becomes more like a single cohort of people receiving an active treatment, with no comparison arm.
People were assigned to the five-drug combination or matching placebos for 12 weeks. During this time, the side effects in both treatment groups were monitored and these could be compared, with itching and anaemia occurring more commonly in the active treatment group.
However, the double-blind drug treatment period was completed at 12 weeks and response outcomes were then assessed 12 weeks later. Twelve weeks later, the active treatm...
Source: NHS News Feed - April 14, 2014 Category: Consumer Health News Tags: Medication Medical practice Source Type: news
FDA Updates Raltegravir (Isentress) Labeling
“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir.
“In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of telaprevir or boceprevir. No dose adjustment is required for Isentress or boceprevir or telaprevir.”
The revised label is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Raltegravir (Isentress) patient fact sheet (Source: AIDSinfo At-a-Glance: Offering Information on HIV/A...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news
Telaprevir Effective for Treating Advanced Hepatitis CTelaprevir Effective for Treating Advanced Hepatitis C
Telaprevir appears effective and relatively safe for treating advanced hepatitis caused by HCV genotype 1, according to an open-label study from Janssen Pharmaceutics. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 29, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Telaprevir-Based Triple Therapy for Chronic Hepatitis CTelaprevir-Based Triple Therapy for Chronic Hepatitis C
How safe and effective is antiviral-based triple therapy for HCV patients with advanced fibrosis? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 15, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Costs for Hepatitis C Treatment SkyrocketCosts for Hepatitis C Treatment Skyrocket
The expense of telaprevir-based triple therapy for hepatitis C and related adverse events far surpasses the amount anticipated from registration trials. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Incivek (Telaprevir Film-Coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 8, 2013 Category: Drugs & Pharmacology Source Type: news
INCIVO data to be presented
Janssen Infectious Diseases-Diagnostics BVBA (Janssen) will present new data for INCIVO® (telaprevir) in combination with peginterferon alfa and ribavirin (PR) at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC, highlighting that earlier treatment improves patient outcomes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 4, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Infectious Disease Latest News Source Type: news
Vertex to Lay off 15% Due to Plunging Hep C Drug Sales
Despite the initial success of Vertex Pharmaceuticals' hepatitis C treatment, Incivek, in 2011, competition from all-oral hepatitis C treatments has damaged sales. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 29, 2013 Category: Pharmaceuticals Source Type: news
Analysis of HCV Variants in Patients Treated With TelaprevirAnalysis of HCV Variants in Patients Treated With Telaprevir
Will patients with HCV respond better to telaprevir with the addition of peginterferon/ribavirin? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
European Commission approves new twice daily dosing of INCIVO®
Janssen Infectious Diseases-Diagnostics BVBA (Janssen) has announced that the European Commission (EC) has approved a new twice daily (BID) dosing of INCIVO® (telaprevir), a direct acting antiviral (DAA) protease inhibitor, in combination with pegylated-interferon and ribavirin (PR) for naive and previous treatment experienced patients. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2013 Category: Drugs & Pharmacology Source Type: news
Updated AIDSinfo Drug Database Offers Health Professionals and Patients the Latest HIV-Related Drug Information
The latest additions to the AIDSinfo drug database provide health care providers and patients with even more information on HIV/AIDS-related drugs.
Recent improvements to the database include:
Investigational HIV drug summaries for health professionals that include the most recent information on pharmacology, dosing, adverse events, and drug interactions. The drug summaries also feature drug compound details from ChemIDplus Advanced (United States National Library of Medicine) and the HIV Drugs in Development Database from the National Institute of Allergy and Infectious Diseases (NIAID).
Updated HIV invest...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 31, 2013 Category: Infectious Diseases Source Type: news
